Skip to main content

Table 3 Clinical cure rate by baseline diagnosis (ME population) at test-of-cure visit

From: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]

  Tigecycline Imipenem/cilastatin Difference Tigecycline-Imipenem/cilastatin
Clinical Diagnosis N % (95% CI) N % (95% CI) % (95% CI)
Complicated appendicitis 128/152 84.2 (77.4, 89.6) 125/145 86.2 (79.5, 91.4) -2.0 (-10.6, 6.7)
Perforation of the intestines 13/21 61.9 (38.4, 81.9) 15/23 65.2 (42.7, 83.6) -3.3 (-32.4, 26.2)
Complicated diverticulitis 12/17 70.6 (44.0, 89.7) 18/25 72.0 (50.6, 87.9) -1.4 (-32.0, 26.7)
Intra-abdominal abscess 11/17 64.7 (38.3, 85.8) 12/17 70.6 (44.0, 89.7) -5.9 (-37.6, 27.4)
Peritonitis 12/14 85.7 (57.2, 98.2) 15/16 93.8 (69.8, 99.8) -8.0 (-38.2, 20.5)
Complicated cholecystitis 11/12 91.7 (61.5, 99.8) 14/16 87.5 (61.7, 98.4) 4.2 (-29.4, 32.4)
Gastric and abdominal perforations 11/13 84.6 (54.6, 98.1) 10/10 100.0 (69.2, 100.0) -15.4 (-46.3, 21.3)
Other 1/1 100.0 (2.5, 100.0) 1/3 33.3 (0.8, 90.6) 66.7 (-42.3, 98.2)
Concomitant bacteremia 10/14 71.4 (41.9, 91.6) 20/27 74.1 (53.7, 88.9) -2.6 (-35.3, 25.4)